<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2027-0119</journal-id>
<journal-title><![CDATA[Urología Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Urol. Colomb.]]></abbrev-journal-title>
<issn>2027-0119</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2027-01192022000200073</article-id>
<article-id pub-id-type="doi">10.1055/s-0042-1744253</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Metabolomic Profile in Patients with Malignant Disturbances of the Prostate: An Experimental Approach]]></article-title>
<article-title xml:lang="es"><![CDATA[Perfil metabolómico en pacientes con alteraciones malignas de la próstata: Un enfoque experimental]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Perdomo]]></surname>
<given-names><![CDATA[Herney Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mena Ramírez]]></surname>
<given-names><![CDATA[Leidy Vanessa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Wist]]></surname>
<given-names><![CDATA[Julien]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[Adalberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Valle School of Medicine ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Valle Faculty of Natural and Exact Sciences Department of Chemistry]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad del Valle  ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad del Valle  ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>73</fpage>
<lpage>81</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2027-01192022000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2027-01192022000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2027-01192022000200073&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Purpose: To identify metabolites in humans that can be associated with the presence of malignant disturbances of the prostate.  Methods: In the present study, we selected male patients aged between 46 and 82 years who were considered at risk of prostate cancer due to elevated levels of prostate-specific antigen (PSA) or abnormal results on the digital rectal examination. All selected patients came from two university hospitals (Hospital Universitario del Valle and Clínica Rafael Uribe Uribe) and were divided into 2 groups: cancer (12 patients) and non-cancer(20 patients). Cancer was confirmed by histology, and none of the patients underwent any previous treatment. Standard protocols were applied to all the collected blood samples. The resulting plasma samples were kept at -80°C, and a profile of each one was acquired by nuclear magnetic resonance (NMR) using established experiments. Multivariate analyses were applied to this dataset, first to establish the quality of the data and identify outliers, and then, to model the data.  Results: We included 12 patients with cancer and 20 without it. Two patients were excluded due to contamination with ethanol. The remaining oneswere used to build an Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) model (including 15 non-cancer and 10 cancer patients), with acceptable discrimination (Q2 = 0.33). This model highlighted the role of lactate and lipids, with a positive association of these two metabolites and prostate cancer.  Conclusions: The primary discriminative metabolites between patients with and without prostate cancer were lactate and lipids. These might be the most reliable biomarkers to trace the development of cancer in the prostate.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Identificar metabolitos en humanos que pueden estar asociados con la presencia de alteraciones malignas de la próstata.  Métodos: Se incluyeron muestras de pacientes masculinos entre 46 y 82 años y que se consideraron en riesgo de cáncer de próstata debido a la elevación del antígeno prostático específico (PSA) o el examen rectal anormal. Todos los pacientes seleccionados procedían de dos hospitales universitarios (Hospital Universitario del Valle y Clínica Rafael Uribe Uribe) y se dividieron en dos grupos: Oncológicos (12) vs no oncológicos (20). El cáncer fue confirmado por histología, y ninguno de ellos recibió tratamiento previo. Se aplicaron protocolos estándar a todas las muestras de sangre recolectadas. Las muestras de plasma resultantes se mantuvieron a -80°Cy se adquirió un perfil de cada muestra mediante RMN. Se aplicaron análisis multivariantes a este conjunto de datos, primero para establecer la calidad de los datos e identificar valores atípicos, y para modelar los datos.  Resultados: Se incluyeron 12 pacientes con cáncer y 20 pacientes sin cáncer. Dos pacientes fueron excluidos por contaminación con etanol. Los restantes se utilizaron para construir un modelo OPLS-DA (15 pacientes no oncológicos y diez oncológicos), con una discriminación aceptable (Q2 = 0,33). Este modelo destacó el papel del lactato y los lípidos, encontrando una asociación positiva entre estos dos metabolitos y el cáncer de próstata.  Conclusiones: Los principales metabolitos discriminativos entre pacientes con cáncer de próstata versus no cáncer fueron el lactato y los lípidos. Estos podrían ser los biomarcadores más confiables para rastrear el desarrollo del cáncer en la próstata.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[prostate neoplasm]]></kwd>
<kwd lng="en"><![CDATA[metabolomics]]></kwd>
<kwd lng="en"><![CDATA[prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[lactate]]></kwd>
<kwd lng="en"><![CDATA[nuclear magnetic resonance]]></kwd>
<kwd lng="es"><![CDATA[neoplasia de la próstata]]></kwd>
<kwd lng="es"><![CDATA[metabolómica]]></kwd>
<kwd lng="es"><![CDATA[cáncer de próstata]]></kwd>
<kwd lng="es"><![CDATA[lactato]]></kwd>
<kwd lng="es"><![CDATA[resonancia magnética]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms]]></article-title>
<source><![CDATA[Ann Transl Med]]></source>
<year>2016</year>
<volume>4</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>206-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Maitland]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The molecular and cellular origin of human prostate cancer]]></article-title>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2016</year>
<volume>1863</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1238-60</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rand]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Rohland]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tandon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[African Ancestry Prostate Cancer GWAS Consortium ELLIPSE/GAME-ON Consortium. Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk]]></article-title>
<source><![CDATA[Hum Mol Genet]]></source>
<year>2016</year>
<volume>25</volume>
<numero>02</numero>
<issue>02</issue>
<page-range>371-81</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mottet]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmunt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Briers]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bolla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cornford]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Guidelines on Prostate Cancer]]></source>
<year>2017</year>
<volume>53</volume>
<publisher-name><![CDATA[European Association of Urology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[T-B]]></given-names>
</name>
<name>
<surname><![CDATA[Drummen]]></surname>
<given-names><![CDATA[GPC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GSTM1 Gene Polymorphism is Implicated in Increased Susceptibility to Prostate Cancer in Caucasians and Asians]]></article-title>
<source><![CDATA[Technol Cancer Res Treat]]></source>
<year>2016</year>
<volume>15</volume>
<numero>06</numero>
<issue>06</issue>
<page-range>NP69-78</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helfand]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Kearns]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Conran]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical validity and utility of genetic risk scores in prostate cancer]]></article-title>
<source><![CDATA[Asian J Androl]]></source>
<year>2016</year>
<volume>18</volume>
<numero>04</numero>
<issue>04</issue>
<page-range>509-14</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimitriadis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kalogeropoulos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Velaeti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2013</year>
<volume>33</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>191-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leyten]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Hessels]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jannink]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2014</year>
<volume>65</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>534-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salami]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Laxman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer]]></article-title>
<source><![CDATA[Urol Oncol]]></source>
<year>2013</year>
<volume>31</volume>
<numero>05</numero>
<issue>05</issue>
<page-range>566-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ilic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Neuberger]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Djulbegovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dahm]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for prostate cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2013</year>
<volume>1</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>CD004720</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Vander Heiden]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mucci]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolomic biomarkers of prostate cancer: Prediction, diagnosis, progression, prognosis, and recurrence]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2016</year>
<volume>25</volume>
<numero>06</numero>
<issue>06</issue>
<page-range>887-906</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsing]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Sakoda]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Chua Jr]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity, metabolic syndrome, and prostate cancer]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>2007</year>
<volume>86</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>s843-57</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spratlin]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Serkova]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eckhardt]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical applications of metabolomics in oncology: a review]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2009</year>
<volume>15</volume>
<numero>02</numero>
<issue>02</issue>
<page-range>431-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sreekumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poisson]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Rajendiran]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2009</year>
<volume>457</volume>
<numero>7231</numero>
<issue>7231</issue>
<page-range>910-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2005</year>
<volume>65</volume>
<numero>08</numero>
<issue>08</issue>
<page-range>3030-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lokhov]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Dashtiev]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Moshkovskii]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Archakov]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolite profiling of blood plasma of patients with prostate cancer]]></article-title>
<source><![CDATA[Metabolomics]]></source>
<year>2010</year>
<volume>6</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>156-63</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serkova]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gamito]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.]]></article-title>
<source><![CDATA[Prostate]]></source>
<year>2008</year>
<volume>68</volume>
<numero>06</numero>
<issue>06</issue>
<page-range>620-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dreiseitl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeifer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry]]></article-title>
<source><![CDATA[Bioinformatics]]></source>
<year>2008</year>
<volume>24</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2908-14</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyagi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Higashiyama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gochi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma free amino acid profiling of five types of cancer patients and its application for early detection]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2011</year>
<volume>6</volume>
<numero>09</numero>
<issue>09</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[TQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics]]></article-title>
<source><![CDATA[J Proteome Res]]></source>
<year>2014</year>
<volume>13</volume>
<numero>07</numero>
<issue>07</issue>
<page-range>3444-54</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Struck-Lewicka]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kordalewska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bujak]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study]]></article-title>
<source><![CDATA[J Pharm Biomed Anal]]></source>
<year>2015</year>
<volume>111</volume>
<page-range>351-61</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pearce]]></surname>
<given-names><![CDATA[JTM]]></given-names>
</name>
<name>
<surname><![CDATA[Athersuch]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ebbels]]></surname>
<given-names><![CDATA[TMD]]></given-names>
</name>
<name>
<surname><![CDATA[Lindon]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholson]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Keun]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Robust algorithms for automated chemical shift calibration of 1D1H NMR spectra of blood serum]]></article-title>
<source><![CDATA[Anal Chem]]></source>
<year>2008</year>
<volume>80</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>7158-62</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<source><![CDATA[R: A Language and Environment for Statistical Computing]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Vienna, Austria ]]></publisher-loc>
<publisher-name><![CDATA[R Foundation for Statistical Computing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Waterman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bonner]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procardis Consortium. The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies]]></article-title>
<source><![CDATA[Mol Biosyst]]></source>
<year>2010</year>
<volume>6</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>215-24</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Sabatini]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer cell metabolism: Warburg and beyond]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2008</year>
<volume>134</volume>
<numero>05</numero>
<issue>05</issue>
<page-range>703-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos Mde]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guedes de Pinho]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarker discovery in human prostate cancer: An update in metabolomics studies]]></article-title>
<source><![CDATA[Transl Oncol]]></source>
<year>2016</year>
<volume>9</volume>
<numero>04</numero>
<issue>04</issue>
<page-range>357-70</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Menendez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hevia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mayo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sainz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2018</year>
<volume>142</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2414-24</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaz]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile]]></article-title>
<source><![CDATA[Int J Biochem Cell Biol]]></source>
<year>2012</year>
<volume>44</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2077-84</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mandhani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sankhwar]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolomics-derived prostate cancer biomarkers: fact or fiction?]]></article-title>
<source><![CDATA[J Proteome Res]]></source>
<year>2015</year>
<volume>14</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>1455-64</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giskeødegård]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Bertilsson]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2015</year>
<volume>113</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1712-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van Guelpen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vollset]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2009</year>
<volume>18</volume>
<numero>05</numero>
<issue>05</issue>
<page-range>1538-43</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crowe]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Appleby]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatty acid composition of plasma phospholipids and riskof prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>2008</year>
<volume>88</volume>
<numero>05</numero>
<issue>05</issue>
<page-range>1353-63</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saylor]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Karoly]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2012</year>
<volume>18</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>3677-85</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kdadra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Höckner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kremer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolomics Biomarkers of Prostate Cancer: A Systematic Review]]></article-title>
<source><![CDATA[Diagnostics (Basel)]]></source>
<year>2019</year>
<volume>9</volume>
<numero>01</numero>
<issue>01</issue>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eidelman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Twum-Ampofo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ansari]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siddiqui]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolic phenotype of prostate cancer]]></article-title>
<source><![CDATA[Front Oncol]]></source>
<year>2017</year>
<volume>7</volume>
<page-range>131</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Giskeødegård]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Tessem]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic alterations in tissues and biofluids of patients with prostate cancer]]></article-title>
<source><![CDATA[Curr Opin Endocr Metab Res]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>23-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dudka]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Thysell]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lundquist]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2020</year>
<volume>20</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>437-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
